Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus
Revolution Medicines (RVMD) drew fresh attention on 10 August 2026 after announcing a multi-part collaboration with BeOne Medicines. The agreement combines joint clinical development and regional rights for key RAS(ON) oncology assets.
See our latest analysis for Revolution Medicines.
The collaboration news comes after a strong period for Revolution Medicines’ share price, with a 42.03% 90-day share price return and an even larger 1-year total shareholder return that indicates strong momentum rather than a short-term spike.
If this kind of move has you looking beyond a single stock, it can be a useful moment to widen your watchlist with 43 healthcare AI stocks
The Revolution Medicines share price has run hard on the BeOne deal, yet valuation estimates span a wide range around the current US$206.97 level. Where does fair value really sit in that spread?
Most Popular Narrative: 1% Overvalued
The most followed narrative places Revolution Medicines’ fair value at about $204.38, slightly below the latest $206.97 close. This frames the current valuation debate.
The analysts have a consensus price target of $204.38 for Revolution Medicines based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $263.0, and the most bearish reporting a price target of just $151.0.
Want to see what sits underneath that narrow fair value gap? The narrative leans on aggressive revenue expansion, margin lift and a rich future earnings multiple. Curious which assumptions really move the model.
Result: Fair Value of $204.38 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Revolution Medicines still faces key risks, including heavy cash use with no current revenue and the possibility that pivotal RAS trials fall short of expectations.
Find out about the key risks to this Revolution Medicines narrative.
Another View: SWS DCF Model Sees Deep Undervaluation
The analyst narrative for Revolution Medicines points to a fair value of $204.38, only slightly below the current $206.97 share price. Yet the SWS DCF model puts intrinsic value near $721.01, which is a very large gap. Is the market underestimating long term cash flows, or is the model too optimistic?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
The mixed signals around Revolution Medicines raise an obvious question. Are investors leaning too far toward the rewards or the risks right now? If you want to move quickly and form your own view based on both sides of the story, start with the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Revolution Medicines?
If Revolution Medicines has sharpened your focus, do not stop here. Use this moment to refresh your watchlist with a few targeted stock ideas.
- Spot potential turnaround stories early by scanning 20 elite penny stocks with strong financials that already show stronger balance sheets and improving fundamentals.
- Target quality at a sensible price by sorting through the 51 high quality undervalued stocks that combine healthier cash flows with more robust financial positions.
- Prioritise resilience by reviewing 83 resilient stocks with low risk scores that score well on financial strength and avoid the most common red flags.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com